Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy

Next Previous
Trial Profile

OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Nivolumab (Primary) ; Capecitabine
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms OXEL

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 28 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top